Abbott's Piramal Acquisition Is $3.72 Billion Push In Emerging Markets With Established Products
This article was originally published in PharmAsia News
NEW DELHI - Abbott is all set to become India's largest pharmaceutical company after it announced a $3.72 billion deal to acquire the domestic formulations business of Mumbai-based Piramal Healthcare, ending months of speculation on which multinational would secure India's fourth-largest pharma compan
You may also be interested in...
Pfizer, Novartis and Abbott reportedly are battling to buy out family-owned Ache, Brazil’s leader in prescription drug sales.
From Pharma To Telecom To Data Analytics, Piramal Surprises Again - To Buy Decision Resources For $635 Mln
India’s takeover tycoon looks at information arbitrage.
Will Innovation Replace Branded Generics As Dominant Strategy For Big Pharma In Emerging Markets? (Part 2 of 2)
[Editor's note: This is part two of a two-part story; part one appeared in PharmAsia News, March 4, 2011.]